42753-75-3

Basic information

• Product Name: METHYL 5-AMINOSALICYLATE
• Synonyms: 5-amino-2-hydroxy-benzoicacimethylester;5-aminomethylsalicylicacid;5-amino-salicylicacimethylester;METHYL 5-AMINOSALICYLATE;METHYL 5-AMINO-2-HYDROXYBENZOATE;5-AMINO-2-HYDROXYBENZOIC ACID METHYL ESTER;5-AMINO SALICYLIC ACID METHYL ESTER;5-Aminomethylsalicylate
• CAS NO: 42753-75-3
• Molecular Formula: C₈H₉NO₃
• Molecular Weight: 167.16
• Product Categories: Aromatic Esters;pharmacetical;C8 to C9;Carbonyl Compounds;Esters;amine|alcohol|carboxylic ester
• Mol File: 42753-75-3.mol
• Article Data: 41

Chemical Properties

• Melting Point: 95-99 °C(lit.)
• Boiling Point: 319.2°Cat760mmHg
• Flash Point: 146.8°C
• Appearance: /
• Density: 1.305g/cm³
• Vapor Pressure: 0.000184mmHg at 25°C
• Refractive Index: 1.605
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
• PKA: 10.02±0.18(Predicted)
• CAS DataBase Reference: METHYL 5-AMINOSALICYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 5-AMINOSALICYLATE(42753-75-3)
• EPA Substance Registry System: METHYL 5-AMINOSALICYLATE(42753-75-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38-43
• Safety Statements: 26
• WGK Germany: 2
• RTECS: VO1683100
• HazardClass: IRRITANT
• Hazardous Substances Data: 42753-75-3(Hazardous Substances Data)

Usage

Uses

5-Amino-2-hydroxybenzoic Acid Methyl Ester is disubsituted benzoic acid used in the preparation of various pharmaceutical compounds such as sphingosine kinase inhibitors.

InChI:InChI=1/C8H9NO3/c1-12-8(11)6-4-5(9)2-3-7(6)10/h2-4,10H,9H2,1H3

Upstream product

• 89-57-6 5-Aminosalicylic Acid 
• 119-36-8 methyl salicylate 
• 96-97-9 5-nitrosalicylic acid 
• 67-56-1 methanol 
• 89-56-5 5-Methylsalicylic acid 
• 7664-93-9 sulfuric acid 
• 17302-46-4 methyl 2-hydroxy-5-nitrobenzoate 
• 51-78-5 p-aminophenol hydrochloride 
• 618-95-1 methyl 3-nitrobenzoate 

Downstream Products

• 80074-18-6 methyl 5-chloroacetamidosalicylate 
• 127882-60-4 4'-O-demethyl-4β-[3''-(methoxycarbonyl)-4''-hydroxyanilino]-4-desoxypodophyllotoxin 
• 151391-80-9 5-{[1-(2,5-Dihydroxy-phenyl)-meth-(E)-ylidene]-amino}-2-hydroxy-benzoic acid methyl ester 
• 1151934-81-4 methyl 5-(3-adamantan-1-ylureido)-2-hydroxybenzoate 
• 1261270-09-0 4-hydroxy-3-(methoxycarbonyl)benzenediazonium tetrafluoroborate 
• 22802-67-1 methyl 2-methoxy-5-aminobenzoate 
• 1343489-68-8 C₂₀H₂₃N₃O₅S 
• 723290-83-3 5-benzenesulfonylamino-2-hydroxy-benzoic acid methyl ester 
• 1352143-66-8 C₁₂H₉F₃N₂O₆S 
• 942404-97-9 methyl 5-((tert-butoxycarbonyl)amino)-2-hydroxybenzoate 
• 791802-85-2 methyl 2-hydroxy-5-(methylsulfonamido)benzoate 
• 1282038-58-7 C₃₈H₃₉FN₈O₇ 
• 1282038-69-0 C₄₂H₄₇N₇O₈ 
• 1282038-85-0 C₂₉H₂₈ClN₅O₅ 

Relevant articles and documents

Inhibition of 3D colon cancer stem cell spheroids by cytotoxic RuII-p-cymene complexes of mesalazine derivatives

The Ru(ii) complex of an imidazole-mesalazine Schiff base is a unique example showing growth inhibition of 3D-colon cancer stem cell spheroids and bulk colon cancer cells at lower dosage than salinomycin or oxaliplatin. Unlike oxaliplatin which increases

MODIFIED PROTEINS AND PROTEIN DEGRADERS

Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.

PYROPTOSIS-INDUCED IMMUNOTHERAPY

Pyroptosis-induced immunotherapy is effected by activating a pore-forming, pyrpotogenic molecule, wherein the activating induces tumor cell pryoptosis and causes tumor regression by T-cell mediated anti-tumor immunity.